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Probiotics for the Prevention of Nosocomial
Diarrhea in Children
Iva Hojsak, yHania Szajewska, z§Roberto B. Canani, zAlfredo Guarino, jjFlavia Indrio,
ySanja Kolacek, Rok Orel, #Raanan Shamir, Yvan Vandenplas, yyJohannes B. van Goudoever,
and zzZvi Weizman, on behalf of the ESPGHAN Working Group for Probiotics/Prebiotics
ABSTRACT
This document provides recommendations developed by the ESPGHAN
Working Group on Probiotics and Prebiotics on the role of probiotics in the
prevention of nosocomial diarrhea in children based on a systematic review
of previously completed systematic reviews and of subsequently published
randomized controlled trials. The quality of evidence was assessed using the
Grading of Recommendations Assessment, Development and Evaluation
guidelines. Recommendations were given only if at least 2 randomized
controlled trials examined the same probiotic strain. Based on currently
available evidence the Working Group recommends using Lactobacillus
rhamnosus GG if the use of probiotics for preventing nosocomial diarrhea in
children is considered.
Key Words: guideline, healthcare-associated, hospital-acquired,
microbiota, randomized controlled trial, systematic review
(JPGN 2018;66: 3–9)
What Is Known
 Nosocomial infections have several negative impacts
on patients and on the healthcare system.
 The incidence of nosocomial diarrhea in children in
developed countries is still high, regardless of
preventive measures.
What Is New
 Overall 8 randomized controlled trials investigated
the role of probiotics in the prevention of
nosocomial diarrhea.
 Currently available evidence showed that adminis-
tration of Lactobacillus rhamnosus GG reduces the
risk of nosocomial diarrhea.
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N osocomial, hospital-acquired, or healthcare-associatedinfections, by definition develop during a hospital stay,
meaning that they are not present or incubating on hospital admis-
sion; usually infections that occur>48 hours after the admission are
considered nosocomial (1). Nosocomial infections have several
negative impacts on patients and on the healthcare system; they
prolong the hospital stay, worsen the treatment outcome, increase
resistance of microorganisms to antimicrobials, and therefore,
significantly increase the cost of health care (2). The incidence
of nosocomial infections in children in developed countries is still
high, ranging from 5.1% to 11.6% depending on time of the year
and type of a hospital ward (3). In children, gastrointestinal infec-
tions account for the majority of hospital-acquired infections (4–6),
and rotavirus is still a major pathogen. There are data implying that
vaccination against rotavirus decreases the nosocomial diarrhea;
however, vaccination is not universally implemented (7). Although
standard preventive measures, mainly hand hygiene, isolation of
sick children, and reduction in the number of hospitalized patients
can decrease infection spreading, they cannot provide total preven-
tion (8,9). The administration of probiotics, defined as live micro-
organisms that, when administered in adequate amounts, confer a
health benefit on the host, on the prevention of nosocomial diarrhea
(10) was reported as a measure for the prevention of nosocomial
diarrhea (11,12).
The aim of this document by the European Society for
Paediatric Gastroenterology, Hepatology and Nutrition (ESP-
GHAN) Working Group (WG) on Probiotics and Prebiotics was
to perform a systematic review of the literature and, based on
relevant evidence, to give recommendations on the use of probio-
tics in the prevention of nosocomial diarrhea. Furthermore, this
review aims to provide clinically relevant data about specific
probiotic strains and doses used in the prevention of nosocomial
diarrhea.
METHODS
The same methodology for developing guidelines pre-
viously used by the WG (13,14) was applied to the current position
paper. The article provides a review of previously completed
systematic reviews and of randomized controlled trials (RCTs)
published after these reviews. The current meta-analysis includes
all published RCTs; this means RCTs included in previous sys-
tematic reviews and RCTs published subsequently. For systematic
reviews/meta-analyses, the Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects (DARE),
and MEDLINE were searched. For subsequently published trials
(starting from the date of the most recent search in the included
reviews), CENTRAL (Cochrane Central Register of Controlled
Trials), MEDLINE, and EMBASE were searched up to
January 2017.
The primary outcome measure was nosocomial diarrhea as
defined by the investigators and regardless of the cause. The
secondary outcome was nosocomial gastroenteritis caused by rota-
virus. Included participants were infants and children up to 18 years
of age. Neonates and premature babies were excluded from the
analysis. As in previous guidelines, the focus was on 6 taxonomic
probiotic groups (Lactobacillus, Bifidobacterium, Saccharomyces,
Streptococcus, Enterococcus, and/or Bacillus).
To assess the methodological quality of the included RCTs,
the Cochrane Collaboration’s tool for assessing risk of bias was
used. The tool includes the following criteria: adequacy of sequence
generation, allocation concealment, and blinding of participants,
personnel and outcome assessors; incomplete outcome data; and
selective reporting (15).
For reporting the effect, the results for individual studies and
pooled statistics are reported as the risk ratio (RR) between the
experimental and control groups with 95% confidence intervals
(CIs). All analyses were based on the random effects model.
Each section of the report represents a summary of the
evidence followed by the key recommendations. Recommendations
are graded by the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system (16) developed
by the Grading of Recommendations Assessment, Development
and Evaluations Working Group. In order to follow the suggested
presentation of recommendations by GRADE, we used the wording
‘‘the WG recommends’’ for strong recommendations, and ‘‘the WG
suggests’’ for conditional (weak) recommendations.
As in our previous documents (13,14), the WG adopted the
position of the US Food and Drug Administration Guidance for
Industry (17) that at least 2 adequate and well-controlled studies,
each convincing on its own, are needed to establish the effectiveness
of an intervention. Consequently, the recommendations were for-
mulated only if at least 2 RCTs that used a given probiotic were
available. If there was only 1 RCT no recommendation was for-
mulated. Moreover, if the strain specification was not given and/or
the probiotic product was not otherwise identifiable, no recommen-
dation was made.
Because of known differences in the effects of different
probiotic strains, the WG gave recommendations only for specific
probiotic strains or combination of strains. Pooled data of all
probiotic trials were presented only for the sake of completeness,
but no recommendation on the use of probiotics in general
was given.
A draft of the article was sent to the WG members for review
and further comments. Comments were discussed by email or in
person, and changes were incorporated as necessary. Recommen-
dations were formulated and graded and disagreement was resolved
by thorough discussion, until full consensus was reached.
RESULTS
Table 1 presents the characteristics of the included RCTs.
Majority of RCTs defined nosocomial diarrhea as passage of 3 or
more loose or watery stools (2,18–23). Only Saavedra et al (24)
defined it as the passage of 5 or more liquid stools a day. Majority of
studies did not report on antibiotic treatment during diarrheal
episodes (19–23).
For the assessment of methodological quality and potential
risk of bias, see Figure 1.
Probiotics Overall
There were 2 systematic reviews and meta-analyses evalu-
ating the role of probiotics in the prevention of nosocomial diarrhea
(11,12).
A 2011 meta-analysis (search date: June 2011), included only
RCTs which investigated the effects of Lactobacillus rhamnosus GG
(LGG). Three RCTs involving 1092 children were identified. Over-
all, this meta-analysis showed that the administration of LGG for the
duration of hospital stay lowered the rate of diarrhea (2 RCTs, RR
0.37, 95% CI 0.23–0.59), and symptomatic rotavirus gastroenteritis
(3 RCTs, RR 0.49, 95% CI 0.28–0.86) (11).
A more recent meta-analysis (12) (search date: June 2013)
included all probiotic strains. Six RCTs involving 1343 participant
met the inclusion criteria. The following strains were evaluated in
included trials: LGG (3 RCTs), L reuteri DSM 17,938 (1 RCT), L
delbrueckii H2B20 (1 RCT), and the combination of Bifidobacter-
ium bifidum and Streptococcus thermophilus (1 RCT).
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The current review included 8 RCTs (6 RCTs already
included in the previous systematic reviews and 2 subsequently
published RCTs) involving 2254 children (2,18–24). One RCT
published in 2016 (25) was excluded from the analysis because the
experimental group received not only a probiotic (LGG) but also
vitamins B and C, and zinc; therefore, positive effect of the
supplementation cannot be attributed solely to LGG.
Overall, treatment with probiotics (as a group) compared
with placebo or no treatment had no effect on the risk of nosocomial
diarrhea (2,18–22,24) (7 RCTs, n¼ 2034, RR 0.72, 95% CI 0.40–
1.28, random effect model). Heterogeneity was found
(Chi2¼ 19.44, P¼ 0.003, I2¼ 69%; Fig. 2).
Probiotics reduced the risk of nosocomial rotavirus diarrhea;
however, the difference between groups was of a borderline sig-
nificance (2,18–21,23,24) (7 RCTs, n¼ 2115, RR 0.65, 95% CI
0.42–1.01). No heterogeneity was found (Chi2¼ 5.89, P¼ 0.44,
I2¼ 0%; Fig. 3).
There was no significant difference in asymptomatic shed-
ding of rotavirus (19,23,24) (3 RCTs, n¼ 356, RR 0.87, 95% CI
0.32–2.37). Heterogeneity was found (Chi2¼ 5.92, P¼ 0.05,
I2¼ 66%; Fig. 4).
Probiotic Strains With Recommendation
Lactobacillus rhamnosus GG
Recommendation: If probiotics for preventing nosocomial
diarrhea in children are considered, the WG recommends
using L rhamnosus GG (at least 109 CFU/day, for the duration
of hospital stay).
Quality of evidence: Moderate
Strength of recommendation: Strong
No new studies were identified after the 2011 systematic
review and meta-analysis (11), which included 3 RCTs
(2,19,23). The LGG dose used in the included studies varied
from 109 CFU/day (2) through 2 1010 CFU/day (23) to
12 109 CFU/day (19).
RCTs varied in the methodological quality; none of the
included studies had a low risk of bias. Limitations included unclear
random sequence generation, unclear allocation concealment,
incomplete outcome data, and selective reporting. Intention-to-treat
analysis was performed in 2 trials. Using the GRADE, the overall
quality of evidence was rated as moderate (Supplemental Digital
Content 1, Table, http://links.lww.com/MPG/B4).
LGG administration reduced the risk of nosocomial diarrhea
from 13.9% to 5.2% (2 RCTs, n¼ 823, RR 0.35, 95% CI 0.19–0.65;
number needed to treat, number needed to treat (NNT), 12, 95% CI
8–21). No significant heterogeneity was found (Chi2¼ 1.26,
P¼ 0.26, I2¼ 21%; Fig. 2).
Three trials (2,19,23) (n¼ 1043) evaluated the effect of LGG
on the risk of rotavirus-induced nosocomial diarrhea. Compared
with the placebo group, in the LGG group the risk of rotavirus
nosocomial diarrhea was reduced; however, the difference between
groups was not significant (RR 0.43, 95% CI 0.17–1.13). No
significant heterogeneity was found (Chi2¼ 2.56, P¼ 0.28,
I2¼ 22%; Fig. 3).
Two studies evaluated the risk of asymptomatic rotavirus
shedding (19,23). There was no difference between groups (RR
1.39, 95% CI 0.74–2.62; Fig. 4).
Lactobacillus reuteri DSM 17938
Recommendation: Because of the lack of efficacy, L reuteri
DSM 17938 should not be considered for the prevention of
nosocomial diarrhea in children.
Quality of evidence: High
Strength of recommendation: Strong
The effect of L reuteri DSM 17938 was evaluated in 2 RCTs
(n¼ 290) (20,21), which showed no effect toward overall noso-
comial diarrhea (RR 1.11, 95% CI 0.68–1.81; Fig. 2) and sympto-
matic rotavirus infection (RR 1.14, 95% CI 0.52–2.52; Fig. 3).
Both studies had a low risk of bias. Using the GRADE, the overall
quality of evidence was rated as high (Supplemental Digital
Content 1, Table, http://links.lww.com/MPG/B4). Studies used
different doses of the same probiotic strain (108 CFU/day (21)
and 109 CFU/day (20)).
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FIGURE 1. Methodological quality summary.
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Probiotics With Insufficient Evidence to Make a
Recommendation
Bifidobacterium animalis subsp lactis (BB-12)
One large (n¼ 727) (18), double-blind, placebo-controlled
RCT demonstrated that administration of B animalis subsp lactis
(BB-12) was not effective in preventing nosocomial diarrhea
occurring more than 48 hours after admission in hospitalized
children older than 1 year (RR 1.46, 95% CI 0.63–3.36; Fig. 2)
or rotavirus diarrhea (RR 0.5, 95% CI 0.05–5.54; Fig. 3). The
incidence of nosocomial gastrointestinal infections was, however,
low in both groups that may have negatively influenced the
outcome. Because there was only 1 RCT with B animalis subsp
lactis (BB-12), the WG cannot make a recommendation for
this strain.
Based in the negative results of this large, high-quality RCT,
it is highly unlikely that the same study will be repeated.
Lactobacillus delbrueckii H2B20
One RCT (n¼ 139) (22) investigating L delbrueckii H2B20
found no difference in the risk for nosocomial diarrhea between
groups (RR 1.55, 95% CI 0.60–4.03; Fig. 2). The risk for rotavirus
infection was not assessed.
Bifidobacterium bifidum and Streptococcus
thermophilus
One RCT (n¼ 55) (24) showed that the combination of B
bifidum and Str thermophilus reduced the risk of nosocomial
diarrhea (RR 0.22, 95% CI 0.05–0.96; NNT 6, 95% CI 3.0–
248.8; Fig. 2). There was no effect of this combination of probiotics
on rotavirus diarrhea (RR 0.36, 95% CI 0.08–1.69; Fig. 3); how-
ever, the rotavirus shedding was reduced (RR 0.27, 95% CI 0.08–
0.87; Fig. 4).
Study or subgroup
1.1.1 L rhamnosus GG (LGG)
Hojsak 2010 19 376 44 366 18.9% 0.42 (0.25, 0.71)
Subtotal (95% CI) 421 402 30.4% 0.35 (0.19, 0.65)
Szajewska 2001 3 45 12
Total events
Heterogeneity: Tau2 = 0.06; Chi2 = 1.26, df = 1 (P = 0.26); I2 = 21%
Test for overall effect: Z = 3.31 (P = 0.0009)
22 56
36 11.5% 0.20 (0.06, 0.66)
Experimental Control Risk ratio
Events Total Events Total Weight M-H, Random, 95% CI
Risk ratio
M-H, Random, 95% CI
Risk of bias
A B C D E F G
+ ? + + + + +
? ? + + + + +
+ + + + + + +
+ + + + + + +
+ + + + + + +
+ + + + – + +
? ? ? ? + + ?
1.1.3 B animalis subsp lactis BB-12
Hojsak 2015 13 362 9 365 15.2% 1.46 (0.63, 3.36)
Subtotal (95% CI) 362 365 15.2% 1.46 (0.63, 3.36)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
13 9
1.1.4 B bifidum and S thermophilus
Saavedra 1994 2 29 8 26 9.2% 0.22 (0.05, 0.96)
Subtotal (95% CI) 29 26 9.2% 0.22 (0.05, 0.96)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 2.01 (P = 0.04)
2 8
1.1.5 L delbrueckii H2B20
Penna 2009 10 72 6 67 13.8% 1.55 (0.60, 4.03)
Subtotal (95% CI) 72 67 13.8% 1.55 (0.60, 4.03)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
10 6
Total (95% CI)
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
1029 1005 100.0% 0.72 (0.40, 1.28)
0.01 0.1 1
Favors experimental Favours control
10 100
Total events
Heterogeneity: Tau2 = 0.39; Chi2 = 19.44, df = 6 (P = 0.003); I2 = 69%
Test for subgroup differences: Chi2 = 15.17, df = 4 (P = 0.004); I2 = 73.6%
Test for overall effect: Z = 1.13 (P = 0.26)
72 101
1.1.2 L reuteri DSM 17938
Urbanska 2016 7 91 6 93 12.8% 1.19 (0.42, 3.41)
Subtotal (95% CI) 145 145 31.3% 1.11 (0.68, 1.81)
Wanke 2011 18 54 16
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 0.03, df = 1 (P = 0.87); I2 = 0%
Test for overall effect: Z = 0.40 (P = 0.69)
25 22
52 18.5% 1.08 (0.62, 1.89)
FIGURE 2. Effect of individual probiotic strains and probiotics as a group for preventing nosocomial diarrhea.
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Study or subgroup
Experimental Control Risk ratio
Events Total Events Total Weight M-H, Random, 95% CI
Risk ratio
M-H, Random, 95% CI
Risk of bias
A B C D E F G
+ ? + + + + +
? ? + + + + +
– ? + + – – +
+ + + + + + +
+ + + + + + +
+ + + + + + +
+ + + + – + +
1.2.1 L rhamnosus GG (LGG)
Hojsak 2010 0 376 2 366 2.0% 0.19 (0.01, 4.04)
Subtotal (95% CI) 535 508 58.7% 0.43 (0.17, 1.13)
Szajewska 2001 1 45 6
Total events
Heterogeneity: Tau2 = 0.23; Chi2 = 2.56, df = 2 (P = 0.28); I2 = 22%
Test for overall effect: Z = 1.72 (P = 0.09)
16 30
36 4.4% 0.13 (0.02, 1.06)
Mastretta 2002 15 114 22 106 52.3% 0.63 (0.35, 1.16)
1.2.3 B animalis subsp lactis BB-12
Hojsak 2015 1 362 2 365 3.3% 0.50 (0.05, 5.54)
Subtotal (95% CI) 362 365 3.3% 0.50 (0.05, 5.54)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
1 2
1.2.4 B bifidum and S thermophilus
Saavedra 1994 2 29 5 26 7.8% 0.36 (0.08, 1.69)
Subtotal (95% CI) 29 26 7.8% 0.36 (0.08, 1.69)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
2 5
Total (95% CI)
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
1071 1044 100.0% 0.65 (0.42, 1.01)
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 5.89, df = 6 (P = 0.44); I2 = 0%
Test for subgroup differences: Chi2 = 3.22, df = 3 (P = 0.36); I 2 = 6.9%
Test for overall effect: Z = 1.91 (P = 0.06)
30 46
1.2.2 L reuteri DSM 17938
Urbanska 2016 1 91 0 93 1.9% 3.07 (0.13, 74.28)
Subtotal (95% CI) 145 145 30.2% 1.14 (0.52, 2.52)
Wanke 2011 10 54 9
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 0.40, df = 1 (P = 0.53); I2 = 0%
Test for overall effect: Z = 0.33 (P = 0.74)
11 9
52 28.3% 1.07 (0.47, 2.42)
0.01 0.1 1
Favors experimental Favors control
10 100
FIGURE 3. Effect of individual probiotic strains and probiotics as a group for preventing nosocomial rotavirus diarrhea.
Study or subgroup
Experimental Control Risk ratio
Events Total Events Total Weight M-H, Random, 95% CI
Risk ratio
M-H, Random, 95% CI
Risk of bias
A B C D E F G
1.4.1 LGG
Subtotal (95% CI) 159 142 70.1% 1.39 (0.74, 2.62)
Szajewska 2001 8 45 4
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 0.09, df = 1 (P = 0.77); I2 = 0%
Test for overall effect: Z = 1.02 (P = 0.31)
22 14
36 31.1% 1.60 (0.52, 4.89)
Mastretta 2002 14 114 10 106 39.0% 1.30 (0.60, 2.80)
1.4.2 B bifidum and S thermophilus
Saavedra 1994 3 29 10 26 29.9% 0.27 (0.08, 0.87)
Subtotal (95% CI) 29 26 29.9% 0.27 (0.08, 0.87)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 2.19 (P = 0.03)
3 10
Total (95% CI)
Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
188 168 100.0% 0.87 (0.32, 2.37)
Total events
Heterogeneity: Tau2 = 0.52; Chi2 = 5.92, df = 2 (P = 0.05); I2 = 66%
Test for subgroup differences: Chi2 = 5.81, df = 1 (P = 0.02); I2 = 82.8%
Test for overall effect: Z = 0.28 (P = 0.78)
25 24
0.01 0.1 1
Favors experimental Favors control
10 100
– + + + – – +
? ? + + + + +
+ + + + – + +
FIGURE 4. Effect of individual probiotic strains and probiotics as a group for preventing asymptomatic rotavirus shedding.
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Adverse Effects
Altogether, 6 studies (2,18–21,24) mentioned adverse
effects. Of these studies, 5 (2,18,19,21,24) found no adverse effects
and 1 study (20) reported no significant difference in the incidence
of adverse effects (ie, abdominal pain, flatulence) between groups.
SUMMARY
The WG recommends choosing a probiotic, the efficacy of
which has been confirmed in well-conducted RCTs, from a man-
ufacturer who has a regulated quality control of factors including
the composition and content of the probiotic agent. If the use of
probiotics for preventing nosocomial diarrhea in children is con-
sidered, the WG recommends using L rhamnosus GG.
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